抗體藥物市場－全球產業規模、佔有率、趨勢、機會和預測：來源、產品、適應症、分銷管道、地區和競爭格局（2021-2031年）

全球抗體醫藥品市場預計將從 2025 年的 793.6 億美元大幅成長至 2031 年的 1,595.2 億美元，複合年成長率為 12.34%。

抗體醫藥品是一種先進的生物療法，由單株或多多株抗體組成，這些抗體經過基因工程改造，能夠特異性結合抗原、中和病原體或調節免疫反應。該領域的發展主要受全球慢性疾病負擔日益加重的驅動，例如自體免疫疾病和癌症。這些疾病需要標靶治療，以期獲得比傳統小分子化合物更高的療效和精準度。然而，臨床開發過程中高昂的成本和複雜的生產過程構成了巨大的經濟障礙，限制了其市場覆蓋範圍和可及性。

據抗體研究協會稱，該領域的監管進展強勁，美國食品藥物管理局（FDA）在2024年核准了15種新型抗體療法。這一數字創下了該治療方法在單一日曆年內獲批核准的最高紀錄，凸顯了該領域創新和接受度的加速發展。

市場促進因素

全球癌症發生率的不斷攀升是抗體醫藥品市場的主要驅動力，也因此迫切需要高度特異性的生物干預手段。隨著癌症患者數量的增加，醫療機構越來越重視單株抗體，這類抗體能夠選擇性地攻擊癌細胞，同時保護健康組織，與全身化療相比，能夠提供更優的治療效果。根據國際癌症研究機構（IARC）2024年2月發布的新聞稿，預計2022年全球新增癌症病例將達到2,000萬例，這印證了對有效治療方法的巨大需求。患者數量的快速成長直接推動了重磅藥物的商業性成功。例如，默克在2024年報告稱，其單株抗體藥物Keytruda的全球銷售額在2023年成長了19%，達到250億美元。

此外，產業領導者之間的策略聯盟和授權協議正在加速抗體藥物複合體（ADC）等下一代技術的研發，並推動市場擴張。製藥公司正積極尋求高價值收購，以整合先進的工程平台並實現產品線多元化，同時避免內部研發所需的漫長週期。這一趨勢促使企業對標靶連接子技術進行大量投資，以提高治療的精準度。例如，強生公司於2024年1月宣布達成最終協議，將以約20億美元收購Ambracs BioPharma，以加強其腫瘤產品組合。此類整合措施簡化了從臨床試驗到商業化的流程，並擴大了尖端治療方案的可近性。

市場挑戰

臨床研發的高昂成本和複雜的生產過程構成了巨大的財務壁壘，嚴重限制了全球抗體醫藥品市場的擴張。這些高昂的成本提高了進入門檻，實際上阻礙了中小型生物技術公司在沒有外部支持的情況下將有前景的候選療法推向市場。因此，該行業仍然由資金雄厚的大型公司主導，削弱了競爭活力，並維持了高定價模式，限制了全球患者的用藥機會和報銷途徑。此外，生物製藥生產固有的複雜性帶來了額外的物流挑戰和財務風險，抑制了對小眾和高風險治療領域的投資。

為了說明這些資金需求的規模，國際藥品製造商協會聯合會（IFPMA）估計，到2024年，開發一種新藥的平均成本將達到26億美元。如此龐大的資金需求迫使製藥公司採取高度規避風險的研發管線策略，將資源集中在那些最有可能獲得監管部門核准的化合物上。因此，這種財務壓力限制了新型抗體醫藥品的研發管線，使投資集中在少數幾個計劃上，而不是治療方法，減緩了市場整體成長速度。

市場趨勢

雙特異性和多特異性抗體平台的廣泛應用，從根本上改變了治療策略，使其能夠同時抑制兩種不同的疾病路徑或將免疫細胞直接靶向腫瘤部位。這項技術進步使研發人員能夠繞過單一特異性療法通用的抗藥性機制，從而在癌症和非癌症疾病中均獲得更強效、更持久的療效，進而提高患者的治療依從性。這種方法的商業性可行性在眼科領域尤其顯著。根據羅氏公司於2024年2月發布的2023年度報告，雙特異性抗體Vabysmo的銷售額預計將達到24億瑞士法郎，證實了雙標靶生物製劑在市場上的強勁需求。

另一個重要趨勢是抗體療法在神經退化性疾病領域的拓展，其治療重點從緩解症狀轉向針對潛在病理（例如澱粉樣蛋白和Tau）的疾病緩解疾病干預。這項進展需要開發專門的診斷和給藥基礎設施，從而為全球老齡化人口打造一個全新的、高附加價值的生物製藥生產領域。Eisai正是這一趨勢的體現。該公司在2024年8月的新聞稿中宣布，其阿茲海默症治療藥物Rekenvi在2024會計年度第一季的全球銷售額達到63億日圓。隨著患者群體的不斷擴大，這一數字環比成長顯著。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球抗體藥物市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依來源（人類單株抗體、人源化單株抗體、嵌合體抗體、鼠源單株抗體）
  • 依產品（單株抗體、抗體藥物複合體）
  • 按適應症（癌症、自體免疫疾病、感染疾病、發炎性疾病、其他）
  • 按分銷管道（醫院藥房、網路藥房、零售藥房）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美抗體藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲抗體藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區抗體藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲抗體藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美抗體藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球抗體藥物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• AbbVie, Inc.
• ADC Therapeutics SA
• AstraZeneca PLC
• Genentech, Inc.
• Genmab A/S
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Pfizer, Inc.
• Hiedelberg Pharma A/G
• Takeda Pharmaceutical Company Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Antibodies Drug Market is projected to expand significantly, rising from USD 79.36 Billion in 2025 to USD 159.52 Billion by 2031, reflecting a compound annual growth rate of 12.34%. Antibody drugs are sophisticated biological treatments consisting of monoclonal or polyclonal antibodies designed to specifically bind antigens, thereby neutralizing pathogens or modifying immune responses. Growth in this sector is primarily fueled by the increasing global burden of chronic diseases, such as autoimmune disorders and cancer, which demand the enhanced efficacy and precision provided by these targeted therapies over conventional small molecules. However, the substantial expenses involved in clinical development and the complex manufacturing processes create major financial hurdles that may limit market reach and accessibility.

According to The Antibody Society, regulatory progress in this field has been robust, with the US Food and Drug Administration approving 15 novel antibody-based therapeutics in 2024. This figure represents a record-breaking number of approvals for this specific therapeutic modality within a single calendar year, highlighting the accelerated pace of innovation and acceptance in the sector.

Market Driver

The rising global prevalence of cancer serves as a major driver for the antibodies drug market, creating an urgent need for highly specific biological interventions. As oncological caseloads grow, healthcare providers are increasingly favoring monoclonal antibodies that can selectively attack tumor cells while preserving healthy tissue, offering superior patient outcomes compared to systemic chemotherapy. Data from the International Agency for Research on Cancer in a February 2024 press release estimated 20 million new cancer cases globally in 2022, a statistic that underscores the immense demand for effective treatments. This surge in patient numbers directly drives the commercial success of blockbuster drugs; for instance, Merck & Co. reported in 2024 that global sales of its monoclonal antibody Keytruda increased by 19% to reach $25.0 billion for the full year 2023.

Furthermore, strategic partnerships and licensing deals among industry leaders are propelling market expansion by expediting the creation of next-generation technologies, such as antibody-drug conjugates. Pharmaceutical firms are actively pursuing high-value acquisitions to integrate advanced engineering platforms and diversify pipelines without enduring the lengthy timelines associated with internal discovery. This trend creates significant investment in targeted linker technologies to improve therapeutic precision, as demonstrated by Johnson & Johnson's January 2024 announcement regarding its definitive agreement to acquire Ambrx Biopharma for approximately $2.0 billion to bolster its oncology portfolio. Such consolidation efforts streamline the path from clinical trials to commercial launch, thereby widening access to cutting-edge therapeutic options.

Market Challenge

The substantial expenses linked to clinical development and the intricate nature of manufacturing processes pose a significant financial hurdle that severely limits the expansion of the global antibody drug market. These prohibitive costs establish a high barrier to entry, effectively preventing smaller biotechnology firms from bringing promising therapeutic candidates to market without outside assistance. As a result, the industry remains dominated by well-capitalized corporations, reducing competitive dynamics and maintaining high pricing models that restrict patient access and reimbursement opportunities worldwide. Additionally, the complexity inherent in biologic manufacturing introduces further logistical challenges and financial risks, thereby discouraging investment in niche or high-risk therapeutic areas.

Highlighting the magnitude of these financial demands, the International Federation of Pharmaceutical Manufacturers and Associations estimated in 2024 that the average cost to develop a new medicine stands at $2.6 billion. This immense capital requirement compels pharmaceutical companies to adopt highly risk-averse pipeline strategies, focusing resources only on compounds with the highest likelihood of regulatory approval. Consequently, this financial pressure restricts the pipeline of new antibody drugs and retards the overall pace of market growth, as investment is concentrated on a select few projects rather than a diverse range of potential therapies.

Market Trends

The widespread adoption of bispecific and multispecific antibody platforms is fundamentally reshaping treatment strategies by allowing for the simultaneous inhibition of two distinct disease pathways or the bridging of immune cells directly to tumor sites. This technological advancement enables developers to bypass resistance mechanisms common in monospecific therapies and enhances patient adherence by delivering more potent and durable responses across both oncological and non-oncological conditions. The commercial viability of this approach is evident in the ophthalmology sector; according to Roche's 2023 Annual Report released in February 2024, the bispecific antibody Vabysmo achieved sales of CHF 2.4 billion, confirming strong market acceptance for dual-targeting biologics.

Another critical trend is the expansion of antibody therapeutics into neurodegenerative diseases, shifting the focus from symptomatic relief to disease-modifying interventions that target underlying pathologies like amyloid and tau. This progression requires the development of specialized diagnostic and infusion infrastructure, establishing a new high-value segment for biological manufacturing tailored to an aging global population. This trajectory is illustrated by Eisai Co., Ltd., which reported in an August 2024 news release that global revenue for its Alzheimer's treatment Leqembi reached JPY 6.3 billion in the first quarter of fiscal year 2024, reflecting a substantial quarter-over-quarter growth as patient access continues to widen.

Key Market Players

• AbbVie, Inc.
• ADC Therapeutics SA
• AstraZeneca PLC
• Genentech, Inc.
• Genmab A/S
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Pfizer, Inc.
• Hiedelberg Pharma A/G
• Takeda Pharmaceutical Company Limited

Report Scope

In this report, the Global Antibodies Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antibodies Drug Market, By Source

• Human mAb
• Humanized mAb
• Chimeric mAb
• Murine mAb

Antibodies Drug Market, By Product

• Monoclonal Antibodies
• Antibody-drug conjugates

Antibodies Drug Market, By Indication

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Inflammatory Diseases
• Others

Antibodies Drug Market, By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Antibodies Drug Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antibodies Drug Market.

Available Customizations:

Global Antibodies Drug Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antibodies Drug Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Source (Human mAb, Humanized mAb, Chimeric mAb, Murine mAb)
  • 5.2.2. By Product (Monoclonal Antibodies, Antibody-drug conjugates)
  • 5.2.3. By Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Others)
  • 5.2.4. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Antibodies Drug Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Source
  • 6.2.2. By Product
  • 6.2.3. By Indication
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Antibodies Drug Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Source
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Indication
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Antibodies Drug Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Source
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Indication
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Antibodies Drug Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Source
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Indication
      • 6.3.3.2.4. By Distribution Channel

7. Europe Antibodies Drug Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Source
  • 7.2.2. By Product
  • 7.2.3. By Indication
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Antibodies Drug Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Source
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Indication
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Antibodies Drug Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Source
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Indication
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Antibodies Drug Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Source
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Indication
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Antibodies Drug Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Source
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Indication
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Antibodies Drug Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Source
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Indication
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Antibodies Drug Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Source
  • 8.2.2. By Product
  • 8.2.3. By Indication
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Antibodies Drug Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Source
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Indication
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Antibodies Drug Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Source
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Indication
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Antibodies Drug Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Source
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Indication
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Antibodies Drug Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Source
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Indication
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Antibodies Drug Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Source
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Indication
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Antibodies Drug Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Source
  • 9.2.2. By Product
  • 9.2.3. By Indication
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Antibodies Drug Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Source
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Indication
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Antibodies Drug Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Source
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Indication
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Antibodies Drug Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Source
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Indication
      • 9.3.3.2.4. By Distribution Channel

10. South America Antibodies Drug Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Source
  • 10.2.2. By Product
  • 10.2.3. By Indication
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Antibodies Drug Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Source
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Indication
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Antibodies Drug Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Source
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Indication
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Antibodies Drug Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Source
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Indication
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Antibodies Drug Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ADC Therapeutics SA
• 15.3. AstraZeneca PLC
• 15.4. Genentech, Inc.
• 15.5. Genmab A/S
• 15.6. Gilead Sciences, Inc.
• 15.7. GlaxoSmithKline PLC
• 15.8. Pfizer, Inc.
• 15.9. Hiedelberg Pharma A/G
• 15.10. Takeda Pharmaceutical Company Limited

16. Strategic Recommendations

17. About Us & Disclaimer